BAT Hosts Successful CORESTA Global Tobacco Science Conference in Edinburgh

Oct.18.2024
BAT Hosts Successful CORESTA Global Tobacco Science Conference in Edinburgh
BAT successfully hosted the CORESTA global tobacco science conference in Edinburgh, focusing on harm reduction and public health opportunities.

On October 17, British American Tobacco (BAT) announced on their official website that the CORESTA Global Congress on Tobacco and Related Products Science was successfully held at the Edinburgh International Conference Center from October 13th to 17th. The event was hosted by BAT, and it brought together over 500 representatives from more than 30 countries, including businesses, research institutions, laboratories, associations, and regulatory bodies. The participants gathered to discuss the prospects of harm reduction in tobacco.


The conference, themed "Advancing Tobacco Harm Reduction through Scientific Collaboration," focused on ways to create smoke-free alternatives for billions of tobacco users. It not only facilitated international dialogue on scientific research related to tobacco and nicotine but also showcased research findings and discoveries from CORESTA members, providing crucial support for the transition from combustible tobacco to smoke-free alternatives.


During the opening ceremony, Danni Tower, Head of Scientific and Regulatory Affairs at the company, gave a keynote speech emphasizing the progress of BAT in advancing tobacco harm reduction agenda. She mentioned that scientific collaboration is crucial in expanding public awareness and acceptance of tobacco harm reduction, and highlighted BAT's commitment to sharing and exchanging world-class scientific research.


The CORESTA conference highlighted the importance of global scientific collaboration to maximize public health opportunities for tobacco harm reduction. We are proud to host such an important event and believe that if all stakeholders recognize the potential for tobacco harm reduction, positive changes could occur globally.


In order to achieve this goal, as discussed this week, there is a need for more open dialogue in the fields of science and regulation. Therefore, we have recently launched Omni™- offering thoughtful ideas for a smoke-free world- which is an open, evidence-based platform based on leading scientific research.


Other keynote speakers at the conference include global health advocate Derek Yach, who spoke on the topic of "New Generation Products Require New Generation Science and Regulation.


The speech at the CORESTA conference showcased the scientific advancements being made using new methods to accelerate harm reduction in tobacco. These advancements ranged from the application of genomics in agricultural science to the development of biomarkers in research, as well as the use of artificial intelligence tools to enhance our understanding of the reasons and effects of interventions. All public health agencies, including the World Health Organization (WHO), should collaborate with CORESTA scientists to expedite change.


BAT stated that the CORESTA conference is just another example of its commitment to promoting public health interests by reducing the harm caused by tobacco globally. The company continues to invest in the development of new smoke-free tobacco products, supported by cutting-edge scientific research and high standards, aimed at laying the foundation for a smoke-free world.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

South Korea’s Tobacco Law Amendment to Include Synthetic Nicotine, Projected to Add Up to $340 Million in Local Tax Revenue
South Korea’s Tobacco Law Amendment to Include Synthetic Nicotine, Projected to Add Up to $340 Million in Local Tax Revenue
Following the National Assembly’s approval of amendments to the Tobacco Business Act on September 22, redefining tobacco to include synthetic nicotine, the Korea Institute of Local Finance (KILF) estimates that local governments could gain between $37 million and $340 million in additional tax revenue in 2025 from tobacco consumption and local education taxes.
Nov.19 by 2FIRSTS.ai
Philippines police seize $200k worth of illegal e-cigarette products, arrest 2 suspects
Philippines police seize $200k worth of illegal e-cigarette products, arrest 2 suspects
Philippine police in Cavite seize $200,000 worth of illegal e-cigarette products, arresting two suspects. Crackdown on smuggling intensifies.
Oct.13 by 2FIRSTS.ai
Product | Dual-flavor, 30,000-puff SKE 2-in-1 launches across multiple UK distributor platforms.
Product | Dual-flavor, 30,000-puff SKE 2-in-1 launches across multiple UK distributor platforms.
E-cigarette brand SKE has listed its “30K Pro Max” bundle across multiple UK e-commerce platforms. The 2-in-1 device features dual flavors with a twist-to-switch design, draw activation, and mesh heating, with a claimed total of up to 30,000 puffs. Across several channels, single-unit pricing ranges from about £8.99 to £10.99.
Oct.24 by 2FIRSTS.ai
Altria Director George Muñoz to Retire After 2026 Shareholder Meeting;
Altria Director George Muñoz to Retire After 2026 Shareholder Meeting;
Altria director George Muñoz plans to retire post-2026 annual meeting, not seeking re-election. Annual meeting expected on May 14.
Oct.15 by 2FIRSTS.ai
62.5% of Vapers Still Use Disposables; 82% for Ages 25–34, Survey Finds
62.5% of Vapers Still Use Disposables; 82% for Ages 25–34, Survey Finds
Vape retailer Haypp reports that 62.5% of vapers still use disposable vapes, rising to 82% among those aged 25–34. 35% of disposable users say they are still buying disposables. Black-market purchases reportedly come mainly from local smaller shops (55%) and specialist vape stores (37%), as well as supermarkets, online retailers and car boot sales. 78.5% of respondents are using pre-ban stock, posing safety risks from aging lithium-ion batteries; 14% plan to continue buying disposables,.
Oct.23 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai